Jingye Zhou, Eccogene CEO
November 9, 2023 03:54 AM ESTUpdated 06:32 AM
Deals
R&D

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Amber Tong

As­traZeneca has re­cruit­ed a new star to its bud­ding GLP-1 show, pick­ing up an ear­ly-stage oral can­di­date from Chi­na’s Ec­co­gene in a deal fea­tur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health ...

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

David Bak­er's lab makes en­zymes with AI, open­ing up the pos­si­bil­i­ty of more pre­cise gene-edit­ing tools

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Agios’ Pyrukynd suc­ceeds in key tri­al of rare red blood cell dis­or­der in kids

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times